RT @RichardPAConway: Makol @AshimaMakol et al. Multimorbidity in SSc . SSc higher burden multimorbidity at diagnosis and

Tweet Author

Tweet Content

Makol @AshimaMakol et al. Multimorbidity in SSc . SSc higher burden multimorbidity at diagnosis and higher risk of developing multimorbidity over time @RheumNow #ACR22 Abstr#1190 https://t.co/VopFI6U5G5 https://t.co/hKKPC7v8EN

Links

Multimorbidity in Systemic Sclerosis: Burden and Trends in Prevalence from an I… https://acrabstracts.org/abstract/multimorbidity-in-systemic-sclerosis-burden-a…

RT @uptoTate: CorEVITAS Abs 1499 #ACRbest #ACR22 cycling to a second line TNFi provides limited benefits to pts with AxS

Tweet Author

uptoTate

Tweet Content

CorEVITAS Abs 1499 #ACRbest #ACR22 cycling to a second line TNFi provides limited benefits to pts with AxSpA who discontinued a first line TNFi. @RheumNow https://t.co/fKDa5kPfXN https://t.co/CtMCj2Ihgc

Links

The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control… http://ow.ly/vp7150LyZMv

RT @RichardPAConway: Mazareeb et al. von Willebrand Factor in systemic vasculitis. Increased in active vasculitis compar

Tweet Author

RichardPAConway

Tweet Content

Mazareeb et al. von Willebrand Factor in systemic vasculitis. Increased in active vasculitis compared to remission and HCs. Correlates disease activity. Not affected by IL6i. @RheumNow #ACR22 Abstr#1573 https://t.co/uJAFHQpOlu https://t.co/PNX0puOeCn

Links

Von – Willebrand Factor, a Possible Marker for Disease Activity in Vasculitis -… https://acrabstracts.org/abstract/von-willebrand-factor-a-possible-marker-for-d…

RT @KDAO2011: Drop PJP prophylaxis in #SLE. Retrospec cohort 4900 SLE on MMF or CYP: 1 case of PJP detected over 2282 pe

Tweet Author

KDAO2011

Tweet Content

Drop PJP prophylaxis in #SLE. Retrospec cohort 4900 SLE on MMF or CYP: 1 case of PJP detected over 2282 person years (incidence rate 0.44/1000 py); PJP prophylx cause neutropenia (IRR 4.7), leukopenia (IRR 4.0), C diff (IRR 3.9), hyperkalemia (IRR 3.7) abst#1594 ACR#22 @rheumnow

RT @DrPetryna: #abs1601 #acr22 @rheumnow gender analysis of RCT 166 PsA pts on UST: F show â¬ï¸ response in resolution

Tweet Author

DrPetryna

Tweet Content

#abs1601 #acr22 @rheumnow gender analysis of RCT 166 PsA pts on UST: F show ⬇️ response in resolution of pain, enthesitis, dactylitis& ACR response rates in both mono and MTXcombo groups. Unlike M, F seem not to benefit from UST+MTX combo for improvement of enthesitis& dactylitis https://t.co/a0uao6eWDO

RT @RichardPAConway: Papagoras et al. Serum GM-CSF increased in AxSpA and persists despite TNFi. Are we going to have a

Tweet Author

RichardPAConway

Tweet Content

Papagoras et al. Serum GM-CSF increased in AxSpA and persists despite TNFi. Are we going to have a trial of mavrilimumab in AxSpA then? @RheumNow #ACR22 Abstr#1156 https://t.co/wCFsY9nC1p https://t.co/lrQQ7tIX4x

Links

Serum Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Is Increased in… https://acrabstracts.org/abstract/serum-granulocyte-macrophage-colony-stimulati…

RT @doctorRBC: BE COMPLETE study: Bimekizumab (IL-17A and IL-17F inhibitor) efficacious in phase 3 trial for treatment o

Tweet Author

doctorRBC

Tweet Content

BE COMPLETE study: Bimekizumab (IL-17A and IL-17F inhibitor) efficacious in phase 3 trial for treatment of PsA. No new safety signals. Abs#1599 @RheumNow #ACR22 https://t.co/iXj7wSRNeK

RT @uptoTate: Abs 1507 at #ACR22 demonstrated that even a 6-month delay in PsA dx from symptom onset contributes to wor

Tweet Author

uptoTate

Tweet Content

Abs 1507 at #ACR22 demonstrated that even a 6-month delay in PsA dx from symptom onset contributes to worse patient-reported outcomes measures on overall quality of life. @RheumNow https://t.co/qLOwE9rImz https://t.co/nacdjz5pCy

Links

Diagnostic Delay of More Than 6 Months Contributes to Poor Patient-Reported Out… http://ow.ly/myh950Lz0qz

RT @ericdeinmd: 13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22 Lab Domains: LAC not always feasible to recheck aCL

Tweet Author

ericdeinmd

Tweet Content

13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22 Lab Domains: LAC not always feasible to recheck aCL, aB2GP IgG higher risk, higher titers (>40U) @RheumNow https://t.co/rcQaqrtDN5

RT @uptoTate: The likelihood of a patient self-reporting LDA/REM and specificity of MDA score were unaffected by which M

Tweet Author

uptoTate

Tweet Content

The likelihood of a patient self-reporting LDA/REM and specificity of MDA score were unaffected by which MDA criteria were met. @DrLauraCoates et al, Abs 1496 #ACR22 @RheumNow https://t.co/xH70swdZZ0 https://t.co/Wct0emTaDt

Links

Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA C… http://ow.ly/qugp50LyXF3

Topics

RT @RichardPAConway: Makol @AshimaMakol et al. Multimorbidity in SSc . SSc higher burden multimorbidity at diagnosis and

RT @uptoTate: CorEVITAS Abs 1499 #ACRbest #ACR22 cycling to a second line TNFi provides limited benefits to pts with AxS

RT @RichardPAConway: Mazareeb et al. von Willebrand Factor in systemic vasculitis. Increased in active vasculitis compar

RT @KDAO2011: Drop PJP prophylaxis in #SLE. Retrospec cohort 4900 SLE on MMF or CYP: 1 case of PJP detected over 2282 pe

RT @DrPetryna: #abs1601 #acr22 @rheumnow gender analysis of RCT 166 PsA pts on UST: F show â¬ï¸ response in resolution

RT @RichardPAConway: Papagoras et al. Serum GM-CSF increased in AxSpA and persists despite TNFi. Are we going to have a

RT @doctorRBC: BE COMPLETE study: Bimekizumab (IL-17A and IL-17F inhibitor) efficacious in phase 3 trial for treatment o

RT @uptoTate: Abs 1507 at #ACR22 demonstrated that even a 6-month delay in PsA dx from symptom onset contributes to wor

RT @ericdeinmd: 13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22 Lab Domains: LAC not always feasible to recheck aCL

RT @uptoTate: The likelihood of a patient self-reporting LDA/REM and specificity of MDA score were unaffected by which M

Do you get our email newsletter?

RT @RichardPAConway: Makol @AshimaMakol et al. Multimorbidity in SSc . SSc higher burden multimorbidity at diagnosis and

RT @uptoTate: CorEVITAS Abs 1499 #ACRbest #ACR22 cycling to a second line TNFi provides limited benefits to pts with AxS

RT @RichardPAConway: Mazareeb et al. von Willebrand Factor in systemic vasculitis. Increased in active vasculitis compar

RT @KDAO2011: Drop PJP prophylaxis in #SLE. Retrospec cohort 4900 SLE on MMF or CYP: 1 case of PJP detected over 2282 pe

RT @DrPetryna: #abs1601 #acr22 @rheumnow gender analysis of RCT 166 PsA pts on UST: F show â¬ï¸ response in resolution

RT @RichardPAConway: Papagoras et al. Serum GM-CSF increased in AxSpA and persists despite TNFi. Are we going to have a

RT @doctorRBC: BE COMPLETE study: Bimekizumab (IL-17A and IL-17F inhibitor) efficacious in phase 3 trial for treatment o

RT @uptoTate: Abs 1507 at #ACR22 demonstrated that even a 6-month delay in PsA dx from symptom onset contributes to wor

RT @ericdeinmd: 13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22 Lab Domains: LAC not always feasible to recheck aCL

RT @uptoTate: The likelihood of a patient self-reporting LDA/REM and specificity of MDA score were unaffected by which M

RT @DrPetryna: #abs1601 #acr22 @rheumnow gender analysis of RCT 166 PsA pts on UST: F show â¬ï¸ response in resolution